Compound doubles up on cancer detection

Tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer, according to a study published last week in the Proceedings of the ...

Oct 08, 2015
popularity42 comments 0

Simplified boron compound may treat brain tumours

Effective and targeted uptake among malignant cells demonstrates the promise of a simplified boron compound for neutron radiation therapy, report researchers at Okayama University and Kinki University.

Sep 16, 2015
popularity21 comments 0

Elephants provide big clue in fight against cancer

Carlo Maley spends his time pondering pachyderms—and cactuses and whales, and a wide array of non-human species—all in pursuit of the answer to this question: Why do some life forms get cancer while others do not?

Oct 09, 2015
popularity258 comments 2

Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2–3 cases per 100,000 people in Europe and North America. According to the WHO classification of the tumors of the central nervous system‎, the standard name for this brain tumor is "glioblastoma"; it presents two variants: giant cell glioblastoma and gliosarcoma. Glioblastomas are also an important brain tumor in canines, and research continues to use this as a model for developing treatments in humans.

Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, antiangiogenic therapy, surgery and experimental approaches such as gene transfer.

With the exception of the brainstem gliomas, glioblastoma has the worst prognosis of any central nervous system (CNS) malignancy, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible, followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic management with corticosteroids. Prognosis is poor, with a median survival time of approximately 14 months.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

New target could eliminate lurking cancer stem cells

Scientists from Trinity College Dublin have identified a novel target that could help to identify 'cancer stem cells' while they are in their inactive state. The scientists could then jolt these cells into action so that ...

How can I tell if she's lying?

Sarcasm, white lies and teasing can be difficult to identify for those with certain disorders – new video inventory developed at McGill may help